Crohn’s & Colitis Foundation of America Announces Winners of Scientific Achievement Awards During Advances in IBD Conference on December 12-14



December 12, 2013

New York, NY- December 12, 2013- The Crohn’s & Colitis Foundation of America (CCFA)  will spotlight three physicians who have made significant contributions to understanding Crohn’s disease and ulcerative colitis and helped improve the quality of life for the 1.4 million Americans affected by these diseases during the 2013 Scientific Achievement Awards ceremony. This awards ceremony will take place during CCFA’s annual Advances in Inflammatory Bowel Diseases conference, held on December 12-14 in Hollywood, FL.

“These physicians’ unwavering work in research is an inspiration to us all,” said Dr. Raymond Cross, Associate Professor of Medicine, Division of Gastroenterology and Hepatology and  Director of the Inflammatory Bowel Disease Program at the University of Maryland School of Medicine. “They will join an illustrious list of scientists whose efforts continue to push the needle forward in the quest for cures to these diseases.”


The award recipients were nominated by the medical and research community for their exceptional dedication to the field of inflammatory bowel diseases (IBD). The winners of the 2013 Scientific Achievement Awards are:


Theodore M. Bayless, M.D.,  Director of Meyerhoff Digestive Disease- Inflammatory Bowel Disease Center at John Hopkins Medicine
Henry D. Janowitz Lifetime Achievement Award
                                                                                          
Brian G. Feagan, M.D., FRCPC, Director of Robarts Clinical Trials at the Robarts Research Institute and Professor of Medicine at the University of Western Ontario
Achievement in IBD Clinical Research Award                                                                                   

Charles Parkos, M.D., Ph.D., Vice Chair and the Director of Experimental Pathology at Emory University School of Medicine
Achievement in IBD Basic Research Award     

                                                                                         
“It is a pleasure honoring these physicians for not only their demonstrated commitment to CCFA, but their tireless contributions and commitment to science,” said Richard Geswell, President and CEO of the Crohn’s & Colitis Foundation of America. “Their hard work and dedication are taking us into a new, exciting era of research.” 


Award recipients

Theodore M. Bayless, M.D.

Dr. Theodore M. Bayless has centered his 50-year medical career at Johns Hopkins, providing personal care for more than 5,000 patients with IBD. Dr. Bayless participated in research in celiac disease, lactose intolerance, Whipple’s disease, cholera, and caffeine to name a few.  His edited textbooks on “Advanced Therapy in Inflammatory Bowel Disease” have provided practical and concise guidance on all aspects of IBD care to thousands of physicians and health care professionals. He is a member of the American Society for Clinical Investigation and a recipient of a Franklin Institute Medal.  He has served as Director of the Immunology, Microbiology and Inflammatory Diseases section of the American Gastroenterological Association (AGA).

                                                                                                             

Brian G. Feagan, M.D. 

Dr. Brian G. Feagan completed his medical degree at the University of Western Ontario in London, Ontario, Canada, with postdoctoral training at the Department of Medicine and Division of Gastroenterology at the University of Western Ontario.  A Fellow of the Royal College of Physicians and Surgeons of Canada, Dr. Feagan holds membership in the Canadian and American Association of Gastroenterology, the American College of Gastroenterology, the College of Physicians and Surgeons of Ontario  and Crohn’s and Colitis Foundation of Canada. Dr. Feagan has authored over 100 articles, book chapters, and monographs and over 200 abstracts. He has also given over 800 presentations at both national and international scientific meetings. His research efforts focus on the design and implementation of randomized controlled trials of therapy for inflammatory bowel disease and he has been the principal investigator on numerous large-scale randomized clinical trials.

     

Charles Parkos, M.D., Ph.D.

Dr. Charles Parkos has had a career-long interest in explaining mechanisms of inflammatory bowel disease. In addition to his research, Dr. Parkos has a longstanding commitment to teaching, training, and mentorship at all levels including graduate and medical students, postdoctoral fellows, and junior faculty. He has served as Director of Emory’s Medical Scientist Training Program since 2007 and helped grow the program. His efforts to promote the discipline of experimental pathology resulted in his election to, and service in, the roles of Vice President (2008-2009), President Elect (2009-2010) and President (2010-2011) of The American Society of Investigative Pathology (ASIP). He received his M.D. /Ph.D. degree from the University of California at San Diego and Scripps Research Institute in 1987.

All three of these award recipients are physicians who have advanced CCFA’s mission while remaining true to the awards’ intent. To find out more about Advances in Inflammatory Bowel Diseases conference, visit: http://www.advancesinibd.org/.

 

About CCFA
The Crohn's & Colitis Foundation of America (CCFA) is the largest voluntary non-profit health organization dedicated to finding cures for Inflammatory Bowel Diseases (IBD). CCFA’s mission is to cure Crohn's disease and ulcerative colitis, and to improve the quality of life of children and adults who suffer from these diseases. The Foundation works to fulfill its mission by funding research, providing educational resources for patients and their families, medical professionals, and the public, and furnishing supportive services for those afflicted with IBD. For more information, visit www.ccfa.org, call 888-694-8872, like us on Facebook, find us on LinkedIn or follow us on Twitter.